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Objective: The pathophysiology of the postpolio syndrome is not fully understood. Increased cytokine
levels in cerebrospinal ﬂuid and peripheral blood indicate a systemic inﬂammatory process. Decreased
cytokine levels and the clinical effect of intravenous immunoglobulin treatment further indicate an
inﬂammatory/immunological pathogenesis. The aim of the present study was to evaluate whether an
autoimmune process follows the initial infection, by means of analyzing immune complexes.
Patients and methods: Circulating immune complexes were analyzed from blood samples of 20 postpolio
patients and 95 healthy controls. To compensate for differences in age between patients and controls, a
sub-analysis was performed using only the 30 oldest controls. Tumor necrosis factor-inducing properties
of polyethylene glycol-precipitated immune complexes were compared between the postpolio patients
and 10 healthy controls.
Results: When comparing levels in postpolio patients to the whole control group, including the 30 oldest
investigated, there were no statistically signiﬁcant differences. No difference was found in tumor necrosis
factor levels induced by immune complexes when comparing patients and controls.
Conclusions: There was no increase in circulating immune complex or in tumor necrosis factor-inducing
effects of circulating immune complex between postpolio patients and healthy controls, indicating that
the postpolio syndrome is not due to an autoimmune reaction.
& 2014 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/3.0/).
1. Introduction
Acute poliomyelitis affects the anterior horn cells causing a
ﬂaccid paralysis. After recovery from acute polio and a stable
period of at least 15 years, new or increasing symptoms including
muscular atrophy, pain, weakness, and fatigue, may develop, a
condition called postpolio syndrome (PPS) [1,2].
Earlier studies have shown that an on-going denervation–
reinnervation process results in an increase in the motor unit
size [3]. When the size of the motor unit areas reaches an upper
limit and denervation is not compensated by reinnervation, there
is a decrease of muscle strength. However, the pathophysiology for
the on-going denervation process is not yet fully understood [2].
Various explanations have been presented including a normal
ageing process, genetic predisposition and immunological factors
[2,4–7]. An increase of cytokine levels in cerebrospinal ﬂuid (CSF),
and peripheral blood (PB) have been reported in PPS patients,
indicating a systemic inﬂammatory process in PPS [5–8]. An
inﬂammatory process is further supported by the ﬁndings of a
recently published study, where PPS patients displayed a disease-
speciﬁc expression of ﬁve distinct proteins [9], and in one study
where PPS patients were found to have elevated leukocyte
myeloperoxidase activity [10]. Furthermore, a decrease in cytokine
levels and a clinical effect of intravenous immunoglobulin (IVIg)
treatment further argues for an inﬂammatory/immunological
pathogenesis of PPS [8,11–14].
One plausible explanation for the inﬂammatory process in PPS
could be an autoimmune process initiated by the polio infection.
Immune complexes (IC) containing antibodies and their corre-
sponding antigens are produced during normal immune responses
as means of eliminating foreign substances, e.g. during infections [15].
In autoimmune diseases, such as systemic lupus erythematosus
(SLE), autoantibodies associate with the corresponding autoanti-
gens producing circulating IC [16]. Increased circulating IC levels
have been found in type I diabetes [17,18] as well as in rheumatoid
arthritis [19]. Thus, increased IC levels can be found in various
diseases, irrespective of the presumed initial pathogenic events.
Whereas SLE is regarded as the prototype IC-mediated type III
disease, other diagnoses with presumed autoimmune pathogen-
esis, like diabetes mellitus and rheumatoid arthritis, are usually
regarded as T-cell dependent diseases sorted in to the type IVa
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group according to the modiﬁed Coombs & Gell classiﬁcation [20].
IC-associated disease can be associated with severe pain [21], and
PPS patients frequently report pain [22]. The pathogenic mechan-
isms relating IC to pain are at present unknown. In clinical studies
of IVIg treatment of PPS patients a positive clinical effect has been
shown regarding pain and it has been suggested that the decrease
in pain may be the primary effect of IVIg in PPS [14].
In the Swedish population, immunity against poliomyelitis
virus is high. Böttiger and colleagues found that antibodies against
the three types of polioviruses were present at the dilution Z1:4
in over 95% of the studied population [23]. In the PPS population,
antibodies against all three polioviruses were still signiﬁcantly
higher than in control groups consisting of patients with Multiple
Sclerosis and other neurological diseases (K. Borg, personal com-
munication 2014). There is, thus, a potential pathophysiological
explanation for the inﬂammatory process in PPS, i.e. the initial
poliovirus infection. There are also indications that a pathological
reaction to the infection may occur. The aim of the present study
was thus to evaluate whether the initial infection is followed by a
delayed exacerbated IC response, which would suggest an auto-
immune process. We have investigated circulating IC levels both
by a conventional C1q binding technique, as well as by analyzing
the cytokine-inducing properties of polyethylene glycol (PEG)-
precipitated IC, as earlier performed in investigations of patients
with SLE [24–27].
2. Patients and methods
2.1. Patients and controls
Circulating IC were analyzed in 20 PPS patients (17 women and
3 men, mean age 64 years (range 38–79 years)) recruited from the
postpolio outpatient clinic, University Department of Rehabilita-
tion Medicine at Danderyd University Hospital, Stockholm,
Sweden. The patients fulﬁlled the criteria for PPS, and participated
in rehabilitation groups specialized for postpolio syndrome. None
of the patients were currently treated with IVIg therapy. Serum
samples were stored at 20 1C until analyzed. The subjects'
consent was obtained according to the declaration of Helsinki,
and the study was approved by the Regional Ethical Review Board
in Stockholm, Sweden.
As negative controls 95 healthy blood donors from the depart-
ment of clinical immunology and transfusion medicine at Uppsala
University Hospital were used (mean age was 42 years (range 20–
69 years) 36 women, 59 men). In order to compensate for the
difference in age between patients and controls, a sub-analysis
was performed using only the 30 oldest controls (with a mean age
of 56 years, 15 women, 15 men (range 50–69 years)). As positive
controls, data on 162 SLE sera previously investigated with the
same technique were used. Samples had been stored at 70 1C.
2.2. Measurement of circulating C1q-binding IC
Measurement was performed using the Quanta Lite C1q CIC
ELISA (Innova Diagnostics, San Diego, CA), according to the
manufacturer's instructions. The lowest point on the standard
curve was 1.23 mg Eq/ml, and the analytical sensitivity was 0.1 mg
Eq/ml. In an evaluation performed by the manufacturer, 9/200
(4.5%) of healthy blood donors had increased levels of CIC410.8
mg Eq/ml.
2.3. Measurement of TNF induction by PEG-precipitated IC
This procedure was performed as previously described [26].
Sera were incubated at 4 1C overnight with equal volume
phosphate buffer saline (PBS) pH 7.4 containing 5% PEG 6000
and 0.1M EDTA. One mIliter PBS containing 5% human serum
albumin (HSA) and 2.5% PEG was added to 1.5ml autoclaved
Eppendorf tubes. Autoclaved plastic cylinders made from 5ml
pipette tips were introduced into the Eppendorf tubes. 1:3 diluted
serum in RPMI-1640 containing 2.5% PEG, were gently placed on
the top of PBS–HSA–PEG layers. The tubes were centrifuged at
2100g and 4 1C for 20min. Supernatants of the less dense RPMI-
1640 solution and the remaining PBS–HSA–PEG were removed
and the PEG-precipitates were dissolved with ice-cold sterile PBS
to the initial volume of serum and stored on ice before cell
stimulation. Meanwhile, buffy coats from healthy blood donors
were diluted 1:4 with sterile PBS and peripheral blood mono-
nuclear cells (PBMC) were separated using Ficoll Paque Plus
density gradient (GE Healthcare Biosciences AB, Uppsala, Sweden).
After removal of supernatants the PBMC were washed twice with
sterile PBS. Mononuclear cells were counted and diluted to
1.1106 cells/ml in cell culture medium RPMI-1640 (Gibco, Life
Technologies, Stockholm, Sweden) supplemented with 1% HEPES,
1% penicillin streptomycin, 10% fetal calf serum (FCS) and 0.5 mU
polymyxin B sulfate. Then, 270 ml PBMC were added to 96-well
polystyrene culture plate and freshly prepared PEG-precipitates
were transferred to the wells (10% vol/vol). After 20 h of incubation
in a 5% CO2 incubator, the supernatants were collected and the
level of cytokine induction by IC were measured in a TNF-α ELISA
using the anti hTNF-α mouse monoclonal IgG1 (MAB610) capture
antibody and the biotinylated hTNF-α goat IgG (BAF210) detection
antibody (R&D Systems, Minneapolis, USA). Due to technical fail-
ure, we obtained no PEG precipitates for two PPS patients as well
for one SLE patient.
2.4. Statistics
Data from the patient and control groups were compared using
the non-parametric Mann–Whitney’s U test. P values o0.05 were
considered as signiﬁcant.
3. Results
There was no difference in levels of circulating IC when values
of PPS patients were compared to those of the controls, including
the group with the 30 oldest controls (p¼0.69 and p¼0.97
respectively). Levels of IC were signiﬁcantly higher among the
SLE patients as compared to the levels of PPS patients and controls
(p¼0.0012 and p¼0.0001 respectively) (Fig. 1). There was no
Fig. 1. Distribution of immune complex levels among 20 PPS patients, 95 healthy
controls, 30 healthy controls with the best age-match compared to the PPS
patients, and 162 SLE patients.
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difference in levels of circulating IC between female and male
control subjects (data not shown). When the occurrence of IC was
investigated by their cytokine-inducing properties no difference
was found between 18 PPS patients and 10 healthy controls.
Supernatant levels of TNF-α were on the other hand signiﬁcantly
higher when PBMC had been stimulated with PEG-precipitates
from four SLE sera with known high IC levels (Fig. 2).
4. Discussion
The aim of the present study was to determine whether or not
there might be an autoimmune reaction causing PPS. The back-
ground to the study was that data from previous studies indicate
an inﬂammatory process in cerebrospinal ﬂuid as well as periph-
eral blood in PPS patients [5,6,8,9,11]. High levels of antibodies,
and a positive clinical effect when the inﬂammation is dampened
by immunological treatment, also indicate an active inﬂammatory
process in PPS [13], and it was speculated that the inﬂammation is
secondary to an autoimmune process. As shown from the results
in the present study there was no increase in IC in PPS patients
when data of the patients were compared with those of healthy
controls. IC was measured both by biochemical means, as levels of
IgG-containing IC binding to C1q, and by functional means, as
levels of TNF-α induced in vitro by PEG-precipitated IC. In both
these investigations, SLE sera known to contain elevated levels of
IC yielded high responses.
There is a possibility that PPS patients might have increased
circulating IC containing mainly IgA or IgM. Although IC containing
IgM (but not IgA) would bind to C1q, they would still not be
detected by the IgG-speciﬁc secondary antibody in our ELISA. We
also think that IC containing only non-IgG isotypes would show
negative reactivity in our functional test, as our previous studies
have shown IC to induce cytokines via the IgG-speciﬁc FcγRIIa
receptor [24,26].
A weakness of the study is the different sex distribution in PPS
patients and controls, but as the analysis did not show any
difference in IC levels between the female and male controls, we
believe that the comparison is still valid.
Thus, further immunological studies are needed in order to
increase the knowledge of the immunological pathophysiology of PPS.
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